Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXG LexaGene	C$0.11 -19.2%	C$0.11	C$0.07 ▼ C$0.31	C$14.77M	2.26	170,061 shs	2.14 million shs
ONC Oncolytics Biotech	C$1.44 +0.7%	C$1.44	C$1.20 ▼ C$4.49	C$108.61M	1.49	79,125 shs	12,862 shs
SQD SQI Diagnostics	C$0.02	C$0.02	C$0.01 ▼ C$0.18	C$6.11M	-0.21	172,133 shs	65,000 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXG LexaGene	0.00%	0.00%	0.00%	0.00%	0.00%
ONC Oncolytics Biotech	-0.69%	-10.06%	+2.88%	-11.73%	-7.74%
SQD SQI Diagnostics	0.00%	0.00%	0.00%	0.00%	-70.00%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LXG LexaGene	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	0.6455 of 5 stars	3.5	0.0	0.0	0.0	1.3	0.0	0.0
SQD SQI Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXG LexaGene	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	3.00	Buy	C$6.00	316.67% Upside
SQD SQI Diagnostics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest SQD, GDR, ONC, BD1, and LXG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/4/2024	ONC Oncolytics Biotech	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	C$3.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXG LexaGene	C$110.93K	133.13	C$0.00 per share	21.25	C$0.01 per share	10.50
ONC Oncolytics Biotech	N/A	N/A	C$0.34 per share	4.22	C$0.37 per share	N/A
SQD SQI Diagnostics	C$3.04M	2.01	C$0.00 per share	8.50	C($0.04) per share	-0.38

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXG LexaGene	-C$8.54M	-C$0.08	N/A	∞	N/A	N/A	-339.54%	-120.21%	N/A
ONC Oncolytics Biotech	-C$27.75M	-C$0.41	N/A	∞	N/A	N/A	-102.66%	-55.47%	5/3/2024 (Estimated)
SQD SQI Diagnostics	-C$19.14M	-C$0.05	N/A	∞	N/A	N/A	N/A	-74.70%	6/4/2024 (Estimated)

Latest SQD, GDR, ONC, BD1, and LXG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	ONC Oncolytics Biotech	-C$0.15	-C$0.05	+C$0.10	-C$0.05	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXG LexaGene	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
SQD SQI Diagnostics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXG LexaGene	138.01	1.39	1.13
ONC Oncolytics Biotech	1.54	9.01	8.86
SQD SQI Diagnostics	464.33	0.12	0.40

Ownership

Institutional Ownership

Company	Institutional Ownership
LXG LexaGene	0.09%
ONC Oncolytics Biotech	6.98%
SQD SQI Diagnostics	25.15%

Insider Ownership

Company	Insider Ownership
LXG LexaGene	17.85%
ONC Oncolytics Biotech	6.24%
SQD SQI Diagnostics	50.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
LXG LexaGene	41	140.64 million	N/A	Not Optionable
ONC Oncolytics Biotech	29	75.42 million	N/A	Not Optionable
SQD SQI Diagnostics	147,000	407.17 million	N/A	Not Optionable

SQD, GDR, ONC, BD1, and LXG Headlines

Source	Headline
	BVAXF BioVaxys Technology Corp. seekingalpha.com - March 28 at 5:01 PM
	SQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy Filing finance.yahoo.com - June 16 at 6:40 PM
	Canadian Investment Regulatory Organization Trading Halt - SQD finance.yahoo.com - June 6 at 10:06 AM
	This SQI Diagnostics Insider Increased Their Holding In The Last Year finance.yahoo.com - May 18 at 1:06 PM
	Closing Bell: Sqi Diagnostics Inc flat on Friday (SQD) theglobeandmail.com - May 17 at 10:10 AM
	Closing Bell: Sqi Diagnostics Inc up on Friday (SQD) theglobeandmail.com - April 29 at 3:21 PM
	Closing Bell: Sqi Diagnostics Inc up on Wednesday (SQD) theglobeandmail.com - April 27 at 12:14 AM
	Closing Bell: Sqi Diagnostics Inc down on Monday (SQD) theglobeandmail.com - April 25 at 2:55 PM
	Closing Bell: Sqi Diagnostics Inc down on Thursday (SQD) theglobeandmail.com - April 21 at 10:35 AM
	Closing Bell: Sqi Diagnostics Inc down on Friday (SQD) theglobeandmail.com - April 15 at 1:43 AM
	Closing Bell: Sqi Diagnostics Inc flat on Wednesday (SQD) theglobeandmail.com - April 12 at 11:06 PM
	Closing Bell: Sqi Diagnostics Inc flat on Tuesday (SQD) theglobeandmail.com - April 11 at 9:11 PM
	SQI DIAGNOSTICS ANNOUNCES ISSUANCE OF PREVIOUSLY ANNOUNCED BONUS WARRANTS finance.yahoo.com - March 20 at 7:09 PM
	SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND DEFERRAL OF CERTAIN INTEREST PAYMENTS ca.finance.yahoo.com - February 6 at 8:47 AM
	The Independent Director of SQI Diagnostics Inc. (CVE:SQD), Gerald Connor, Just Bought 5.8% More Shares finance.yahoo.com - December 9 at 7:16 AM
	SQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND ANNOUNCES DEFERRAL OF CERTAIN INTEREST PAYMENTS finance.yahoo.com - October 19 at 5:59 PM
	SQI Diagnostics: Top 10 Undervalued Medical Diagnostics & Research Industry Sector Stocks on TSX Venture Exchange (SQD) theglobeandmail.com - September 19 at 12:56 AM
	SQI Diagnostics reports Q3 results seekingalpha.com - August 30 at 11:19 PM
	New York State Approves SQI Diagnostics' EXACT COVID-19 Antibody Assay finance.yahoo.com - March 3 at 4:45 PM
	SQI DIAGNOSTICS PROVIDES UPDATE ON PREVIOUSLY ANNOUNCED ASSET PURCHASE TRANSACTION WITH PRECISION BIOMONITORING newswire.ca - February 10 at 6:47 AM
	SQI DIAGNOSTICS PROVIDES UPDATE ON PREVIOUSLY ANNOUNCED ASSET PURCHASE TRANSACTION WITH PBI DIAGNOSTICS finance.yahoo.com - February 9 at 8:46 PM
	Stocks in play: SQI Diagnostics Inc ca.finance.yahoo.com - January 31 at 4:56 PM
	Wilmot Matthews Is The Non-Independent Director of SQI Diagnostics Inc. (CVE:SQD) And They Just Picked Up 8.1% More Shares yahoo.com - November 6 at 10:05 AM
	SQI Diagnostics Appoints Andrew Morris as Chief Executive Officer, and Grants Options wfmz.com - September 13 at 6:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
Tesla Stock Drops on Weak Delivery Numbers and it May Fall More
April 2, 2024 11:25 AM
View Tesla Stock Drops on Weak Delivery Numbers and it May Fall More
Intel's Foundry Woes: Sell Signal or Silver Lining Ahead?
April 5, 2024 8:45 AM
View Intel's Foundry Woes: Sell Signal or Silver Lining Ahead?
Tesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?
March 26, 2024 7:00 AM
View Tesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?
Cannabis: One Stock to Play the Movement
April 8, 2024 8:38 AM
View Cannabis: One Stock to Play the Movement

All Headlines

Company Descriptions

LexaGene

CVE:LXG

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.

Oncolytics Biotech

TSE:ONC

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

SQI Diagnostics

CVE:SQD

SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, it offers microarray tests for protein and antibody testing workflow. The company was founded in 1999 and is headquartered in Toronto, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial